The failure of oxaliplatin to show a benefit in adjuvant therapy for elderly patients is not well understood. The discordance between clinical trial outcomes for oxaliplatin treatment in elderly patients when given in adjuvant therapy, and when given in the treatment of metastatic disease, cannot be explained based on current data.
The role of adjuvant therapy for patients with stage II colon cancer has not been well defined.
Studies currently underway
ECOG E5202, comparing adjuvant FOLFOXSystemic chemotherapy using a combination of the drugs Leucovorin (folinic acid), Fluorouracil, and Oxaliplatin. alone with FOLFOXSystemic chemotherapy using a combination of the drugs Leucovorin (folinic acid), Fluorouracil, and Oxaliplatin. plus bevacizumab in patients with high-risk Stage II colon cancer, was closed prematurely due to the lack of benefit from the addition of oxaliplatin in other studies. No outcome data have yet been reported.
Future research priorities
Future research priorities include:
- improved risk stratification for patients based on existing and emerging tumour tissue and blood prognostic markers
- real-time markers of adjuvant therapy benefit.